
    
      A randomized, double blind, controlled trial will be conducted in general intensive care unit
      (ICU) in Tehran, Iran. After a full review of the inclusion and exclusion criteria and
      explanation of the risks and benefits of the study, written consent form will be completed.
      The participants are 200 eligible hospitalized patients with enteral feeding in ICU, aged â‰¥
      18 years. Intervention patients will be received 0.3 g/kg/day of glutamine along with enteral
      formula for 28 days and control patients will be received maltodextrin along with enteral
      formula for 28 days. Patients will be evaluated for occurrence of new infection, organ
      failure, duration of stay in ICU, 28 days and 6 months mortality and inflammatory and immune
      markers.
    
  